In glutamine metabolism, the GLS inhibitor CB-839 has entered clinical trials for treating hematologic malignancies, colorectal cancer, melanoma, NSCLC, TNBC, and others [168]. This evidence concerns the gene GLS and non-small cell lung carcinoma.